Uncategorized

Novo Nordisk left praying to Artemis and Hermes to salvage CKD program after phase 3 fail

Published

on

A phase 3 trial of Novo Nordisk’s ziltivekimab has missed its primary endpoint, denting the prospects of a molecule analysts tipped to generate blockbuster sales and diversify the company’s portfolio. Novo has chances to rescue the program with its ongoing Artemis and Hermes trials.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version